A Phase I/II Study Evaluating the Safety and Efficacy of Vaccination With Autologous Dendritic Cells Loaded With Tn-MUC1 Peptide in Patients With Non-Metastatic Androgen Independent Prostatic Adenocarcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 Sep 2016 Status changed from active, no longer recruiting to completed.
- 27 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.